T-regulatory cells in tumour-specific vaccination strategies.
BACKGROUND
Immunotherapy against cancer does not result in impressive clinical responses. Failure of vaccine-induced T-cell-mediated immunotherapy to improve therapeutic results occurs for many reasons, including regulatory networks imposed by growing tumours, intrinsic properties of cancer cells, suboptimal design of therapeutic vaccines and subversion of the immune system. Most vaccines are incapable of inducing strong immunity, the vaccine's capacity to induce effector T cells is blocked by regulatory T cells (Tregs) in the lymph nodes, the vaccine-induced T cells are not able to infiltrate the tumour, tumour-infiltrating T cells cannot exert their effector function due to locally present Tregs and/or vaccines may induce/boost Tregs.


OBJECTIVE
We focus on the negative effects of Tregs in cancer immunotherapy and highlight potential therapeutic options to counteract these.


CONCLUSIONS
Interplay and balance between Tregs and effector cells determines the efficacy of vaccines and thereby clinical outcome.
Welters
Marij J P
MJ
Department of Immunohematology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Piersma
Sytse J
SJ
van der Burg
Sjoerd H
SH
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
D019496:Cancer Vaccines